Burning Rock Biotech Ltd. entered a collaboration with IMPACT Therapeutics to provide testing services for IMPACT’s development of its ATR inhibitor IMP9064, which received IND clearance...
IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S.